
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group Inc. is poised for significant growth, driven by sustained high-single-digit sales growth and an expected expansion of EBITDA margins from approximately 16% today to the mid-20s in the coming years, highlighting the company's financial resilience. The firm’s solid, unlevered balance sheet provides a strong foundation for future growth initiatives, underpinned by the increasing global adoption of advanced diabetes technologies, which has accelerated over the past 15 years. Furthermore, the International segment's consistent double-digit sales growth, supported by new product launches such as MiniMed Go and the Instinct CGM sensor, positions the company favorably for continued revenue and market share expansion.
Bears say
Minimed Group Inc faces significant challenges that contribute to a negative outlook, including anticipated declines in EPS due to the launch of new products and unresolved regulatory risks related to its pipeline of devices, which could result in delays and increased costs. The company has experienced competitive disadvantages owing to past quality system issues and exhibits low penetration rates in key markets; approximately 26% for Type 1 diabetes and only 6% for intensive Type 2 diabetes patients, indicating underperformance relative to its estimated patient population. Additionally, the company's historical struggles with meeting product development timelines add to the concern, as these delays may position Minimed Group behind faster-moving competitors in the medical technology space.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares